Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum

SARS-CoV-2 Omicron BA.4 和 BA.5 从疫苗和 BA.1 血清中逃逸抗体

阅读:5
作者:Aekkachai Tuekprakhon ,Rungtiwa Nutalai ,Aiste Dijokaite-Guraliuc ,Daming Zhou ,Helen M Ginn ,Muneeswaran Selvaraj ,Chang Liu ,Alexander J Mentzer ,Piyada Supasa ,Helen M E Duyvesteyn ,Raksha Das ,Donal Skelly ,Thomas G Ritter ,Ali Amini ,Sagida Bibi ,Sandra Adele ,Sile Ann Johnson ,Bede Constantinides ,Hermione Webster ,Nigel Temperton ,Paul Klenerman ,Eleanor Barnes ,Susanna J Dunachie ,Derrick Crook ,Andrew J Pollard ,Teresa Lambe ,Philip Goulder ,Neil G Paterson ,Mark A Williams ,David R Hall ,Jiandong Huo ,Juthathip Mongkolsapaya ,Jingshan Ren ,David I Stuart ,Gavin R Screaton

Abstract

The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread rapidly to become globally dominant and has split into a number of sublineages. BA.1 dominated the initial wave but has been replaced by BA.2 in many countries. Recent sequencing from South Africa's Gauteng region uncovered two new sublineages, BA.4 and BA.5, which are taking over locally, driving a new wave. BA.4 and BA.5 contain identical spike sequences, and although closely related to BA.2, they contain further mutations in the receptor-binding domain of their spikes. Here, we study the neutralization of BA.4/5 using a range of vaccine and naturally immune serum and panels of monoclonal antibodies. BA.4/5 shows reduced neutralization by the serum from individuals vaccinated with triple doses of AstraZeneca or Pfizer vaccine compared with BA.1 and BA.2. Furthermore, using the serum from BA.1 vaccine breakthrough infections, there are, likewise, significant reductions in the neutralization of BA.4/5, raising the possibility of repeat Omicron infections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。